Compare Amplify Cybersecurity ETF (HACK) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Johnson & Johnson — how do they compare? Amplify Cybersecurity ETF trades at $125.61 (market cap $3.55B), while Johnson & Johnson trades at $256.46 (market cap $622.84B). The key difference: Johnson & Johnson is far larger — about 175.4× Amplify Cybersecurity ETF's market cap, and Johnson & Johnson pays a 2.07% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 30 Days and Johnson & Johnson for 129 Days on average.
| HACK | JNJ | |
|---|---|---|
Market Cap | $3.55B | $622.84B |
Volume | 233,961 | 5,277,426 |
Sector | Sector/Thematic | Health |
52-Week High | $127.66 | $278.43 |
52-Week Low | $70.69 | $186.00 |
Typical Hold Time | 30 Days | 129 Days |
Enterprise Value | — | $651.12B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $125.81, down 1.45% today but near its 52-week high, with a strong technical outlook showing bullish moving averages and key support at $124. Recent news highlights the ETF's momentum, driven by AI safety concerns and cybersecurity demand, with the fund up 84.96% from its 52-week low. Financial ratios are not disclosed for this ETF, but sector growth remains a tailwind.
The outlook for HACK is positive, supported by rising cybersecurity spending and AI-driven threats, though risks include increased short interest and sector volatility. Analyst sentiment is bullish, with the ETF positioned to benefit from ongoing digital security trends, but investors should monitor competitive and macroeconomic pressures.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% today, with a bearish technical signal but strong fundamentals including a 21.48% net income margin and consistent earnings beats. The stock is supported by a diversified healthcare portfolio and a recent dividend declaration of $1.34 payable in September 2026. Revenue growth is projected to reach $97.9B in 2026, though net income is expected to moderate. Analyst consensus is bullish with a $286.53 price target, but technical indicators show resistance near $260.
JNJ presents a solid long-term investment opportunity due to its robust profitability, high ROE of 25.74%, and defensive sector positioning. Risks include increasing debt-to-asset ratio (24.06% in 2025) and competitive pressures in pharmaceuticals. The stock's current valuation at a P/E of 29.98 may limit near-term upside, but analyst optimism and dividend reliability support a positive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
